# US 2026/0096985 A1 · Injectable Composition For Drug Delivery > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0096985 A1 - Document ID: US20260096985A1 - Status: Published application - Kind: A1 - Application number: 19/348,865 - Filed: 2025-10-03 - Published: 2026-04-09 - Earliest claimed: 2024-10-07 - Assignees: Celanese EVA Performance Polymers LLC - Applicants: Celanese EVA Performance Polymers LLC - Inventors: Vijay Gyanani; Jeffrey Haley - Web page: https://patentgrep.com/patent/US20260096985A1 ## CPC - A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)} - A61K 31/499: Spiro-condensed pyrazines or piperazines - A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 31/551: having two nitrogen atoms, e.g. dilazep - A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem - A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract An injectable composition for delivering a therapeutic agent is provided. The injectable composition includes one or more polymers including a poly ortho ester (POE) polymer. The POE polymer has a Tg of between about −10° C. and 110° C. as determined in accordance with ASTM E1640-18. The injectable composition also includes one or more solvents and one or more therapeutic agents. The one or more therapeutic agents includes a basic therapeutic agent. Methods for treating a condition in a patient are also provided. ## Claims ### Claim 1 An injectable flowable composition for delivery of one or more therapeutic agents, comprising: one or more polymers comprising a first poly ortho ester (POE) polymer wherein the first POE polymer has a Tg of between about −10° C. and 110° C. as determined in accordance with ASTM E1640-18; one or more solvents; and one or more therapeutic agents, wherein the one or more agents comprises a basic therapeutic agent. ### Claim 2 (depends on 1) The injectable gel composition of claim 1, wherein the one or more therapeutic agents constitute from about 40 wt. % to about 70 wt. % of the composition. ### Claim 3 (depends on 1) The injectable gel composition of claim 1, wherein the POE polymer has an acetal monomer content of from about 20 mol. % to about 80 mol. %. ### Claim 4 (depends on 1) The injectable gel composition of claim 1, wherein the POE polymer has a polyol monomer content of from about 20 mol. % to about 80 mol. %. ### Claim 5 (depends on 4) The injectable gel composition of claim 4, wherein the polyol monomer content comprises from about 1 mol. % to about 60 mol. % of one or more modified polyols. ### Claim 6 (depends on 1) The injectable gel composition of claim 1, wherein the POE polymer has a weight-average molecular weight of from about 1 kDa to about 100 kDa. ### Claim 7 (depends on 1) The injectable gel composition of claim 1, wherein the first POE polymer has a Tg of between about −10° C. and 50° C. as determined in accordance with ASTM E1640-18. ### Claim 8 (depends on 1) The injectable gel composition of claim 1, wherein the solvent comprises an organic solvent. ### Claim 9 (depends on 1) The injectable gel composition of claim 1, wherein the organic solvent comprises N-methyl-2-pyrrolidone (NMP), 2-pyrrolidone, dimethyl sulfoxide (DMSO), benzyl benzoate, benzyl alcohol, triacetin, glycofurol, polyethylene glycol, ethyl acetate, or mixtures thereof. ### Claim 10 (depends on 9) The injectable gel composition of claim 9, wherein the organic solvent comprises NMP. ### Claim 11 (depends on 1) The injectable gel composition of claim 1, wherein the one or more therapeutic agents comprise one or more antipsychotics. ### Claim 12 (depends on 11) The injectable gel composition of claim 11, wherein the one or more antipsychotics comprise risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and functional analogues thereof. ### Claim 13 (depends on 1) The injectable gel composition of claim 1, wherein the therapeutic agent is in crystalline form. ### Claim 14 (depends on 1) The injectable gel composition of claim 1, comprising a second POE polymer. ### Claim 15 (depends on 14) The injectable gel composition of claim 14, wherein the second POE polymer has a glass transition temperature (Tg) that is greater than the first POE polymer. ### Claim 16 (depends on 1) The injectable gel composition of claim 1, wherein the composition forms an in situ implant upon injection. ### Claim 17 (depends on 1) A method for prohibiting and/or treating a condition, disease, and/or cosmetic state of a patient in need thereof, the method comprising injecting the composition of claim 1 in the patient.